Company Description
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally.
The company’s products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology.
It offers regenerative dermal and soft tissue fillers; 3D-bioprinted regenerative breast implants; rhcollagen-based commercial bioink for regenerative medicine applications, such as Collink.3D 50L, a bioink in powder form; Collink.3D 90, an rhCollagen-based bioink solution for use in a variety of 3D bioprinting applications; and Collink.3D 50, an rhCollagen-based bioink product.
The company also provides VergenixSTR, a soft tissue matrix, intended for the treatment of tendinopathy; and VergenixFG, a wound healing flowable gel, intended for the treatment of chronic and acute wounds.
It has collaboration agreements with AbbVie; STEMCELL; the Advanced Regenerative Manufacturing Institute; Stratasys; and RegenMed Development Organization.
The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019.
CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
| Country | Israel |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 57 |
| CEO | Yehiel Tal |
Contact Details
Address: Weizmann Science Park, 4 Oppenheimer Rehovot, 7670104 Israel | |
| Phone | 972 73 232 5600 |
| Website | collplant.com |
Stock Details
| Ticker Symbol | CLGN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001631487 |
| CUSIP Number | 19516R107 |
| ISIN Number | IL0004960188 |
| SIC Code | 3842 |
Key Executives
| Name | Position |
|---|---|
| Eran Rotem CPA | Deputy Chief Executive Officer and Chief Financial Officer |
| Yehiel Tal | Chief Executive Officer and Director |
| Oren Fahimipoor | Vice President of Operations |
| Dr. Elana Gazal | Vice President of Research and Development |
| Prof. Oded Shoseyov | Founder and Chief Scientist |
| Hadas Dreiher Horowitz | Vice President of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 15, 2025 | 6-K | Report of foreign issuer |
| Mar 26, 2025 | 20-F | Annual and transition report of foreign private issuers |
| Mar 26, 2025 | 6-K | Report of foreign issuer |
| Feb 24, 2025 | 6-K | Report of foreign issuer |
| Feb 12, 2025 | 6-K | Report of foreign issuer |
| Jan 28, 2025 | SCHEDULE 13G/A | Filing |
| Nov 27, 2024 | 6-K | Report of foreign issuer |
| Sep 25, 2024 | 6-K | Report of foreign issuer |
| Aug 20, 2024 | 6-K | Report of foreign issuer |
| Aug 20, 2024 | 6-K | Report of foreign issuer |